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Abstract
This chapter will introduce the reader to the pathophysiology of two devastating neuro-
logic events, traumatic brain injury (TBI) and acute ischemic stroke (AIS). Here we focus 
on the role of key pro-inflammatory and anti-inflammatory cytokines. Several experi-
mental interventions have been found to modulate cytokine production and brain injury 
after AIS or TBI. Here minocycline, biological response modifiers, hormonal therapies, 
omega-3 fatty acids, N-acetylcysteine, and cannabinoids will be discussed. In addition, 
the role of cytokine-induced inflammasomes in both TBI and AIS will be addressed and 
followed by discussion of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-18, and 
IFN-γ). Finally, the main anti-inflammatory cytokines, IL-33, IL-10, IL-6, and IL-4, will 
be discussed in the context of both TBI and AIS. It should be noted that the role of these 
cytokines is diverse and the dichotomization of classically pro-versus anti-inflammatory 
cytokines is being re-examined, as many of these cytokines have been found to play dual 
roles in TBI and AIS brain injury.
Keywords: traumatic brain injury, ischemic stroke, cytokines, interleukins, 
inflammasome
1. Pathophysiology of traumatic brain injury
Traumatic brain injury (TBI) is a major cause of death and disability worldwide [1, 2]. It is 
one of the most commonly diagnosed neurological disorders in the United States, impact-
ing people of a variety of ages and segments of society [3]. In Europe, the economic cost of 
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TBI is over 33 billion euros per year [4]. Continued surveillance and research is being done 
to reduce primary and secondary TBI [as well as acute ischemic stroke(AIS)]–induced brain 
injury [1].
The pathophysiology of TBI begins with the initial brain trauma (i.e., the primary injury). 
This primary injury results from mechanical damage that disrupts the blood-brain barrier 
(BBB), alters the vasculature and damages brain tissue. The resulting injured glia and neurons 
release their intracellular contents (i.e., damage-associated molecular patterns; (DAMPs)) into 
the extracellular space and activate neighboring glia and neurons. Activated glia and neu-
rons then produce molecular signals that can both exacerbate and mend the acute injury and 
contribute to long-term recovery [5–9]. These downstream molecular and cellular processes 
(i.e., the secondary injury in TBI) are the focus of many pre-clinical and clinical therapeutic 
studies. Secondary injury in TBI involves a host of molecular and cellular responses to the 
Figure 1. AIS and TBI pathophysiology. The pathophysiology of AIS and TBI share common mechanisms. The initial 
insult in AIS, an occlusion of blood flow resulting in a core infarct zone surrounded by a poorly perfused penumbra, 
versus the initial primary physical impact in TBI both result in perfusion and metabolic dysregulation leading to decreased 
glucose delivery and resultant adenosine triphosphate (ATP) depletion. The depletion of ATP prevents ATP-dependent 
ion pumps from regulating ionic gradients across cell membranes. As a result, there is aberrant neurotransmitter release 
and fluxes of ions like calcium causing excitotoxic cell death and cell injury via the activation of downstream molecules, 
like proteases. Cell damage leads to the release of damage-associated molecular patterns (DAMPs) which bind to pattern 
recognition receptors (PRRs) to exacerbate neuroinflammation via inflammasome formation, and astroglial, microglial, 
neuronal, and endothelial cell activation; these cells orchestrate the release of numerous cytokines, both pro-and anti-
inflammatory. Blood-brain barrier disruption also occurs following the initial brain injury in TBI and AIS, permitting 
the influx of peripheral immune cells that exacerbate the inflammatory response through cytokine release, free radical 
release, and complement cascade activation. Further oxygen free radical production and reperfusion cellular injury 
occurs due to re-establishment of blood flow after its blockade in AIS. Abbreviations: AIS, acute ischemic stroke; 
ATP, adenosine triphosphate; BBB, blood-brain barrier; DAMP, Damage-associated molecular patterns; PRRs, pattern 
recognition receptors; TBI, traumatic brain injury.
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primary impact including: (a) an influx of peripheral inflammatory cells through the disrupted 
BBB leading to the release of reactive oxygen species (ROS), cytokines, chemokines, and free 
radicals; (b) the excessive release of excitatory neurotransmitters in response to ion imbalance 
across the cell membrane following adenosine triphosphate (ATP) depletion and metabolic 
dysregulation; and (c) significant increases in intracellular calcium concentration that contrib-
ute to protease, nuclease and lipase/phosphatase activation [10]. All of these factors culminate 
in cellular dysfunction and cell death/loss via rapid necrotic and more delayed (e.g., apoptotic) 
cell death pathways (See Figure 1).
The spatiotemporal distribution of pro- and anti-inflammatory cytokine production in sec-
ondary injury is a key feature of TBI pathophysiology and the development of post-TBI 
acute, sub-acute and chronic disability and recovery. By examining the role of individual 
cytokines in these processes, we can expect to identify novel approaches to TBI intervention/
therapy.
2. Pathophysiology of ischemic stroke
Stroke is the fifth leading cause of death worldwide. Each year it affects approximately 
800,000 people [11, 12]. Of all the people affected by stroke, two-thirds either die or are dis-
abled [13]. Ischemic stroke constitutes 87% of all stroke cases [14]. The initial acute insult 
occurs when a thrombus or embolus lodges in one of the cerebral arteries. This blockage 
produces cellular and chemical changes in the ischemic core and the ischemic penumbra (the 
periphery of the lesion which receives some collateral blood flow from other arteries). The 
lack of perfusion to the ischemic core causes brain cells to die and release their intracellular 
contents due to a lack of ATP. The intracellular contents act as DAMPs to trigger neuroin-
flammatory cascades, while decreased perfusion in the ischemic penumbra leads to aber-
rantly functioning brain cells [15]. Macrophage scavenger receptor 1 and other macrophage 
receptors clear DAMPs and when deleted in a mouse model of AIS exacerbated neurologic 
deficits and infarct size [16]. Congruently, increased expression of Mafb, a transcription factor 
that promotes the expression of macrophage scavenger receptor 1, decreased the severity of 
post-AIS deficits [16].
Glutamate is also released in AIS and interacts with glutamate receptors in the penumbra 
resulting in excitotoxicity. This along with a state of energy depletion increases influx of 
sodium and calcium into the cells, resulting in membrane and cytoskeletal disintegration, 
enzyme activation, and eventual cell death [17]. Neuroinflammation, driven by cytokine pro-
duction and complement activation, leads to the recruitment and adhesion of leukocytes 
into the CNS and endothelial surface and increases BBB disruption [15]. Subsequent reper-
fusion, although essential to protect brain tissue from further ischemic injury, is respon-
sible for “reperfusion injury” by initiating additional inflammatory cascades; cytokines, free 
radicals and degradation enzyme activation as well as recruitment of leukocytes from the 
periphery further aggravate these processes [18]. This additionally causes mitochondrial 
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damage, phospholipid membrane breakdown, cytoskeletal disintegration and cell death (See 
Figure 1) [18].
There is increasing emphasis on the importance of ongoing inflammatory processes in the 
pathophysiology of stroke. Neuroinflammation is central to ischemic stroke pathophysiology 
from the initial endothelial activation within minutes to hours post-insult to the post-injury 
reparative phases occurring over days to months [8, 15]. Cytokine signaling plays an espe-
cially extensive role in the pathophysiology of stroke and in the reparative mechanisms and 
residual deficits detected post-stroke. They also contribute to behavioral changes following 
AIS that include post-stroke depression, apathy, fatigue, as well as post-traumatic stress and 
anxiety (i.e., related to the presence of various cytokines and neuroinflammatory changes) 
[19–25].
3. The role of cytokines in central nervous system injury
3.1. What are cytokines?
Cytokines are small, secreted proteins released by many brain parenchymal cells and infil-
trating immune cells (i.e., via autocrine, paracrine or endocrine actions) that influence the 
interaction and communication between cells. Historically, cytokines have been defined as 
lymphokines (when secreted by lymphocytes), monokines (when secreted by monocytes), 
chemokines (having chemotactic/attractant properties) and interleukins (cytokines made by 
one leukocyte that act on other leukocytes) [26]. Importantly, many brain cells (i.e., other cell 
types) can release cytokines. Cytokines have been broadly classified based on their recep-
tor homology, their overall action as pro-versus anti-inflammatory, or their membership into 
the tumor necrosis factor, lymphokine, interleukin (IL-) and interferon (IFN-) families [9]. 
Cytokine receptor classes include the tumor necrosis factor receptor family, interleukin-1 
receptor family, Class-II cytokine receptor family which includes interferon receptors and the 
IL-10 receptor, and Class-I or hematopoietin cytokine receptors which includes receptors of 
the IL-2, IL-3, and IL-6 family, as well as homodimeric receptors [9, 27–30].
Similar to their effects in the periphery, CNS cytokines are known to regulate the production 
of other cytokines. They can also alter the BBB, recruit inflammatory cells and influence neu-
rotransmitter metabolism (monoamines, serotonin, dopamine and glutamate) [31–33]. In AIS 
and TBI, activated glial and neuronal cells both produce and respond to anti- and pro-inflam-
matory cytokines, influencing reparative and destructive mechanisms after brain injury has 
occurred. The balance of these reparative and destructive processes influences post-stroke 
and post-TBI outcomes.
3.2. Pro-inflammatory cytokines
In AIS and TBI, tissue injury and hypoxia activate microglia, the endogenous brain immune 
cells and a major source of pro-inflammatory cytokines in the CNS [8]. Pattern recognition 
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receptors (PRRs) on microglia detect DAMPs triggering microglia to transition to vari-
ous phenotypes, some of which promote the production of pro-inflammatory cytokines 
or anti-inflammatory cytokines. Classically, microglia have been characterized as M1 (i.e., 
pro-inflammatory) versus M2 (anti-inflammatory) phenotypes [34]. However, the classic 
nomenclature is under scrutiny, as many studies have demonstrated results incongruent 
with the simple categorization of M1 versus M2. Microglia are dynamic cells, continuously 
changing and responding to local stimuli. The M1/M2 polarization scheme does not neces-
sarily fully capture the versatility of microglia behavior along a pro- to anti-inflammatory 
continuum [35]. Microglia contribute to neurodegeneration through the release of pro-
inflammatory cytokines such as IL-1β, TNF-α, and IFN-γ, and via promotion of cytotoxic 
levels of ROS, reactive nitrogen species, nitric oxide, glutamate, and histamine [27, 34, 36]. 
Additionally, other CNS effector cells such as astrocytes, neurons, oligodendrocytes, CNS-
derived macrophages and mast cells contribute to the pro-inflammatory cytokine milieu 
post-injury [37–39]. The pro-inflammatory cytokines TNF-α and IL-1β, as well as IL-6, are 
also involved in the initiation of sickness behaviors and may be related to post-AIS and post-
TBI recovery responses [40].
Post-AIS and post-TBI inflammatory changes may be deleterious or beneficial. Several studies 
show that the inflammatory response in AIS relates to infarct volume and the inflammatory 
response in TBI to injury severity and contusion volume. While some studies consistently 
demonstrate deleterious roles of cytokines such as TNF-α, others are inconsistent in polariz-
ing cytokines as pro-versus anti-inflammatory [41–48]. Thus, the roles of cytokines in TBI and 
AIS are still unclear and while categorization of cytokines as pro-versus anti-inflammatory is 
helpful, it is not definitive in all cases.
3.3. The inflammasome and pro-inflammatory cytokine release
Inflammasomes play a major role in the release of pro-inflammatory cytokines and the induc-
tion of cell death in TBI and AIS. Multiple molecules join together due to the activation of 
PRRs by DAMPs to form inflammasomes specific to their PRR. Inflammasomes can be formed 
in the cytoplasm of a variety of cells (neurons, microglia, macrophages, brain endothelial 
cells) [49] and upregulate cytokines that augment the inflammatory response [50]. The stan-
dard inflammasome is composed of a PRR in the cell cytosol connected to the protease cas-
pase-1 by an adaptor protein. In TBI and AIS, NLRP1 and NLRP3 inflammasomes are formed 
in microglia and neurons in response to DAMPs [51, 52]. NLRP1 and NLRP3 are both formed 
via cytosolic NOD-like PRRs (i.e. NLR) with a carboxy-terminal leucine-rich repeat, nucleo-
tide-binding domain, and pyrin domain; these components permit interactions with an adap-
tor apoptosis-associated speck-like protein (ASC) which contains a caspase activation and 
recruitment domain to permit the activation of caspase-1 (See Figure 2, Key concepts box) [50, 
53]. Activated caspase-1 goes on to activate cytokines IL-1β and IL-18 while triggering apop-
totic cell death. The NLRP1 inflammasome can additionally recruit various cell molecular 
responses including the membrane channel pannexin-1, the X-linked inhibitor of apoptosis 
protein (XIAP), caspase-5, caspase-11, and P2X purinoreceptor 7 to guide its activation and 
actions in various cell types [50].
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Figure 2. The Inflammasome. Inflammasome complexes form in response to activation via DAMPs or cell signaling 
molecules produced in states of cell stress and injury. Cytoplasmic or transmembrane PRRs recognize DAMPs 
and initiate the assembly of the inflammasome complex and the transcription of cytokine precursors. The typical 
inflammasome complex is composed of a PRR connected via an adaptor protein to caspase-1. Through PRR activation 
by DAMPs, caspase-1 is activated and initiates an inflammatory cascade involving the activation of the cytokines 
IL-18 and IL-1β as well as cell death mechanisms. The inflammasome depicted above is representative of the NLRP3 
inflammasome of the NLR family of pattern recognition receptors. The NOD-like receptor pattern recognition receptor 
is a cytoplasmic receptor complex containing a leucine rich repeat, pyrin domain, and nucleotide-binding domain. It is 
activated by DAMPs/molecular pattern signals to activate caspase-1 which it is connected to via the apoptosis-associated 
speck-like protein, an adaptor protein. Activated caspase-1 cleaves pro- IL-18 and IL-1β to their active forms to promote 
neuroinflammation and cell death mechanisms. Abbreviations: ASC, apoptosis-associated speck-like protein; DAMP, 
Damage-associated molecular patterns; LRR, carboxy-terminal leucine-rich repeat, NB domain, nucleotide-binding 
domain; NLR, NOD-like receptor; PRR, pattern recognition receptor. See Key Concept Box.
Key Concept Box:
Key components of the inflammatory response in AIS and TBI
DAMPs (Damage-associated molecular patterns)-intracellular contents and products released from damaged cells that 
act as molecular signals to trigger neighboring and infiltrating cells to respond, thus promoting inflammation. DAMPs 
interact with PRRs on cells to recruit additional cells and organize an inflammatory response.
PRRs (Pattern recognition receptors)-a receptor that recognizes the molecular signatures associated with damage 
or pathogen invasion to activate downstream signal transduction and the formation of the inflammasome complex. 
DAMPs or pathogen-associated molecular patterns (PAMPs) bind to their respective PRR, triggering the downstream 
inflammatory response.
Inflammasome-large multiprotein complexes named after their respective PRR (e.g. NLRP1, named for the NOD-like 
receptor, NLR). These complexes have been observed in astrocytes, microglia, and neurons. The standard inflammasome 
is composed of a PRR attached to an adaptor protein linking it to a protease, classically, caspase-1, which goes on to 
cleave and activate cytokines IL-1β and IL-18. Cell death is triggered via activation of these cytokines and pyropoptosis.
Cytokines-small proteins secreted by immune cells both centrally and peripherally to relay information between cells 
and trigger immune responses and cell interactions to be protective or damaging. Cytokine actions include the recruit-
ment of immune cells, alteration of the BBB, alteration of neurotransmitter metabolism, angiogenesis, astrogliosis, the 
promotion of other cytokines, protease activation, activation of apoptotic cell death mechanisms, and many more.
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NLRP3 inflammasomes were found in astrocytes, microglia and cortical neurons in a weight-
drop model of TBI in rats [54]. Protein levels of NLRP3, active caspase-1, and IL-18 all gradu-
ally increased over the course of 7 days in cortical tissue ipsilateral to the contusion, while 
levels of IL-1β rose at 6 h post-injury and declined over the course of 7 days to sham levels [54]. 
In support of the role of NLRP3 in TBI, another animal study showed that the expression of 
NLRP3, caspase-1, and thioredoxin-interacting protein (TXNIP), a regulator of NLRP3 activity, 
were all increased in the cerebral cortex of rats at 12 and 24 h post-blast injury [55]. In a fluid-
percussion model of TBI in rats, NLRP1 inflammasome complexes containing ASC, caspase-1, 
caspase-11, XIAP, and pannexin-1 with resultant caspase-1 activation and XIAP cleavage were 
present in injured cortical lysate at 4 h post-injury. These complexes were also localized to 
cortical neurons [52]. Thus, the NLRP3 inflammasome is implicated in multiple mechanisms 
of brain injury ranging from diffuse blast injury to localized fluid percussion injury in animal 
models and may translate to patients with different mechanisms of brain injury as well.
A single immediate intracerebroventricular post-TBI dose of anti-ASC antibody, an anti-
body targeting the ASC component of the NLRP1 and NLRP3 inflammasome complex, 
decreased the activation of caspase-1, IL-1β and XIAP cleavage at 24 h post-injury. This 
same intracerebroventricular dose followed by booster anti-ASC antibody injections intra-
peritoneally (i.p.) at 24 and 48 h post-TBI significantly decreased the lesion volume at 3 days 
post-injury [52]. In contrast, a study using the controlled-cortical impact (CCI) TBI model 
in NLRP1 knockout mice and ASC knockout mice found no differences in the recovery of 
motor function up to 14 days post-injury in wild-type injured mice versus knockout mice; 
there were also no differences in lesion volume or the number of dead cells in the cortex or 
dentate gyrus ipsilateral to the injury at 3 days post-injury, despite an observed decrease in 
IL-1β at 1 day post-injury. Interestingly, the level of IL-6 also decreased in NLRP1 knock-
outs [56]. These findings suggest a role for additional inflammatory mediators in determin-
ing histological and behavioral outcomes post-injury. The baseline versus injury-induced 
inflammatory environment may influence post-injury outcomes, dictating the amount and 
type of cytokines necessary to produce a certain outcome. Knockout animals have a com-
pletely different baseline inflammatory environment with potentially alternate mechanisms 
of immune activation.
In humans, higher cerebrospinal fluid (CSF) levels of inflammasome complex components 
caspase-1, ASC, and NACHT leucine rich repeat protein-1 (NALP-1) were associated with sig-
nificantly poorer outcomes as determined by unfavorable versus favorable Glasgow outcome 
scores at 5 months post-injury in moderate-severe TBI patients [57]. Similiarly, increased 
levels of inflammasome proteins, NLRP1, NLRP3, as well as caspase-1 and IL-1β have been 
detected in ipsilateral brain tissue samples of stroke patients [58].
Preclinically, in a rodent and neuronal culture model of AIS, Fann et al. showed an upregula-
tion of NLRP3, NLRP1, caspase-1, IL-18 and IL-1β. The authors then used a caspase-1 inhibi-
tor to thwart detrimental post-ischemia effects, reducing neuronal cell death in the culture 
model and functional deficits and infarct volumes in the mouse model [58]. These findings 
showcase the role of caspase-1 in post-ischemic deficits, a downstream component of many 
inflammasome complexes.
The NLRP1 inflammasome also plays a role in AIS. In a study by Abulafia et al. using a throm-
boembolic mouse model of stroke, NLRP1 was detected in microglia post-stroke as early as 
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6 h as compared to sham mice (NLRP1 was expressed in neurons and astrocytes, but not in 
microglia in sham mice). Despite this finding, the overall concentration of NLRP1 in cortical 
lysates was no different than shams [51]. In this same study, intracerebroventricular injection 
of anti-NLRP1 antibody 15 min post-thromboembolic stroke reduced caspase-1 and IL-1β 
activation at 24 h, but did not affect infarct volume. These results are similar to the results 
from the NLRP1 knockout mice studies in TBI. While the reduction in caspase-1 and IL-1β 
activation via anti-NLRP1 in Abulafia’s study evidences the role of NLRP1 in inflammasome 
formation post-stroke, it does not distinguish NLRP1’s relative importance to other inflam-
masomes formed post-stroke. In a rodent model of stroke, the NLRC4 (NLR family, CARD 
domain containing 4) and AIM2 (absent in melanoma 2) inflammasomes were shown to con-
tribute to brain injury without NLRP3 involvement (i.e., without this inflammasome com-
monly involved in brain injury) [58–61]. Furthermore, knock-out mice (NLRC4−/−, AIM2−/−, 
ASC−/−) studies all show an improvement in function following AIS with decreased microglia 
activation, decreased leukocyte recruitment and decreased infarct volume [59]. These discov-
eries identify the NLRC4 and AIM2 inflammasomes in addition to the NLRP3 inflammasome 
as potential therapeutic targets for stroke and provide new insights into how the inflamma-
tory response is regulated post-stroke.
3.4. Inflammatory cytokine–tissue necrosis factor-α (TNF-α)
TNF-α can interact with two receptor subtypes: TNF receptor type 1 (TNFR1) or type 2 
(TNFR2). TNF-α binds to TNFR1 or TNFR2 triggering the formation of intracellular com-
plexes (complex 1, 2a, 2b, and 2c in TNFR1 and complex 1 in TNFR2) to promote inflamma-
tion, apoptosis, neurodegeneration, necroptosis, as well as some aspects of cell survival and 
proliferation through respective signal transduction pathways [62]. TNFR1 activation is clas-
sically associated with the exacerbation of cell injury and the promotion of cell death, while 
TNFR2 is associated with cell survival and proliferation, but has also been associated with 
inflammation and apoptosis [62–64].
TNF-α is among the first cytokines upregulated following TBI and AIS and is involved in 
the regulation of microglia activation as well as glutamatergic synaptic and glial signaling 
[64, 65]. Two biologically active forms of TNF-α, a soluble form and a transmembrane form, 
can be released primarily by microglia in inflammatory conditions, in addition to astrocytes, 
endothelial cells, and neurons. Many studies in a variety of animal models of mild to severe 
TBI have detected increased levels of TNF-α post-injury [66–69].
3.5. TNF-α in TBI
In TBI patients, increased levels of TNF-α have been detected in the CSF for up to 22 days 
after injury and have been noted in varying degrees in post-mortem tissue from TBI brain 
samples taken early post-injury (less than 17 min survival time) versus late post-injury (6–122 
h survival time) [70, 71]. Tissue from the cortex ipsilateral to injury in both the early group 
and late group showed higher levels of TNF-α than controls. Specifically, the late group had 
TNF-α concentrations approximately five times higher than the early group, and higher levels 
of TNF-α in the contralateral cortex as compared to controls [71].
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In animal models of TBI, TNF-α inhibition has resulted in protective effects. The lipophilic 
analog of thalidomide, 3,6′ dithiothalidomide, an inhibitor of TNF-α synthesis, ameliorated 
Y-maze spatial memory deficits and deficits in novel object recognition at 7 days post-injury 
when dosed up to 12 h post-mild TBI injury in mice [69]. Another TNF-α synthesis inhibitor, 
pentoxifylline, and a TNF-α activity inhibitor, TNF-α binding protein, improved edema at 
24 h and motor deficits at up to 14 days post-injury as measured by rats’ neurologic severity 
score in a closed head injury weight drop model of TBI in the rat [72]. The effect of pentoxifyl-
line on motor recovery being reversible with administration of recombinant TNF-α [72].
TNF-α has demonstrated dual effects based on timing post-injury. In a study examining motor 
function and lesion severity in TNF-α knockout mice at 48 h post-injury, TNF-α knockouts had 
better motor function [73]. However, at 2 and 4 weeks post-injury, TNF-α knockouts had worse 
motor function and more cortical tissue loss than wildtype mice [73]. In another study, mice 
lacking the mitogen activated protein kinase (MAPK), p38α, a downstream signaling mecha-
nism in microglia known to promote TNF-α and IL-1β cytokine release (p38α knockout mice) 
were examined in a model of diffuse TBI using fluid percussion injury causing massive microg-
lia activation. Interestingly, in the TBI-injured p38α knockout mice, TNF-α levels were actually 
higher than wildtype TBI-injured mice at 6 h post-injury and returned to baseline levels by 7 
days post-injury, alongside the reversal of motor deficits on rotarod and a decrease in activated 
microglia morphology in p38α knockout TBI-injured mice [74]. These findings support addi-
tional sources of TNF-α post-TBI and contrast the role of other microglia-induced cytokines to 
TNF-α in aspects of functional recovery post-TBI.
In a closed head injury model of TBI in mice, the expression of the complement system’s 
C5a receptor was examined in TNF/lymphotoxin-α knockout mice. C5a is an anaphylatoxin 
involved in neutrophil and glial cell chemotaxis to the site of injury as well as neuronal apop-
tosis [75, 76]. The TNF/lymphotoxin-α knockout TBI mice experienced high levels of C5a 
receptor in neurons, neuroglia, and neutrophils at 24 and 72 h, similar to wild-type TBI mice, 
but displayed lower C5a receptor levels than the wild-type TBI mice by 7 days post-injury; 
sham-injured knockout mice had low levels of C5a receptors [77]. These findings emphasize 
the importance of the timing of cytokines in the regulation of the immune response post-TBI, 
as lack of TNF-α decreased C5a receptor expression at only 7 days post-TBI.
3.6. TNF-α in AIS
In AIS patients, TNF-α has been demonstrated in neurons and astrocytes in brain tissue 
within the first 24 h and for up to 18 days post-stroke; TNF-α immunoreactivity overlapped 
many TUNEL stained dying cells in the infarct core and peri-infarct region within the first 
days post-stroke, spreading as far as the contralateral hemisphere by 1.6 days in one case [78]. 
In patients, TNF-α was also found to be a good marker of ischemia in peripheral blood at 24 h 
post-stroke [79]. Peripheral TNF-α can induce the production of MCP1/CCL2 which not only 
help to recruit monocytes into the CNS [80], but also induce leukocyte rolling and adhesion to 
cerebral vasculature via E- and P-selectins [81].
In a pre-clinical study by Botchkina et al. examining AIS and TNF-α expression, TNF-α 
was increased locally in astrocytes, microglia, choroid plexus cells, endothelial cells, and in 
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 infiltrating polymorphonuclear cells; neurons expressed maximal levels of TNF-α by 6 h post-
stroke, and were surrounded by activated microglia. TNF-α regulates microglial activation as 
well as glutamatergic glial and synaptic transmission [82]. Apoptotic neurons were also found 
to express TNF-α at 24 h post-stroke [83]. TNF-α expression in AIS results in the upregulation 
of MMP-9 and other metalloproteinases that increase BBB permeability; the increased BBB 
permeability permits entry of leukocytes, proteases, immunoglobulins and thrombin into the 
CNS, facilitating cell injury [84–86]. Higher baseline peripheral levels of MMP-9 were corre-
lated with larger lesion volumes in stroke patients [79].
Higher levels of TNF-α are generally related to worse outcomes in AIS. Mice genetically 
modified to overexpress TNF-α have larger infarct volumes post-stroke, as well as increased 
neuronal apoptosis [87]. Barone et al. showed that administration of TNF-α prior to AIS 
resulted in worse functional deficits and larger infarcts that were reversed via neutralization 
with anti-TNF-α antibody. The pre- and post-stroke intracerebroventricular administration 
of anti-TNF-α antibody or soluble TNF-receptor I also decreased infarct size in this study 
[88]. The soluble TNFR1 receptors sequester the TNF-α that has already been released due to 
AIS, thus helping reduce ischemic injury. Additional studies administering TNF-α neutral-
izing antibodies or soluble TNF-α receptor post-stroke result in smaller lesion volumes and 
less cerebral edema [86, 89]. A study by Pan et al. on TNF-α trafficking across the BBB post-
stroke found that mice who underwent AIS had higher levels of TNF-α transported across 
the BBB on day 5 post-stroke in both hemispheres, cortically and subcortically without an 
increase in overall BBB permeability. This finding was substantiated by a peak number of 
TNFR1 and TNFR2 receptors in endothelial cells ipsilateral to the ischemic site at 5 days post-
stroke that would permit this selective uptake across the BBB. However, interestingly, these 
increases in TNF-α transport peaked while functional deficits began to improve [90]. Thus, 
the observed time course of increased TNF-α levels in this study may additionally impli-
cate TNF-α in post-stroke repair and neuroplasticity. Further evidence of TNF-α’s potential 
benefit is seen via its ability to activate the formation of the TNFR1-TRADD (TNF receptor 
associated protein death domain) complex to induce NF-κB mediated transcription of anti-
apoptotic proteins, contributing to cell survival. However, TNF-α can also induce cell death 
via recruitment of caspases and proteins like Fas-associating protein with a death domain 
(FADD)[64].
3.7. TNF-α polymorphisms
In both AIS and TBI, single-nucleotide polymorphisms (SNPs) in TNF-α have been correlated 
to different risk profiles for disease severity [91–93]. A meta-analysis on AIS risk in individu-
als with TNF-α-308G/A gene versus-238G/A gene polymorphisms, both of which lead to high 
TNF-α production, suggests differences in AIS risk associated with these SNPs in Caucasians 
versus Asians; the TNF-α-308G/A gene polymorphism was protective in Asians, while the 
TNF-α-238G/A gene polymorphism was associated with a higher risk of AIS in Caucasians 
[92]. In a study of the TNF-α-308G/A gene polymorphism in TBI patients, those with this 
polymorphism had worse clinical outcomes as measured by the Glasgow outcome scale at 6 
months post-injury [93].
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3.8. Inflammatory cytokine–interleukin-1β
IL-1β is an essential mediator in the neuroinflammatory response, is constitutively expressed 
in the CNS, and is upregulated minutes after a neuronal insult [94]. As previously mentioned, 
pro- IL-1β is cleaved by caspase-1 into its active form [94]. The transcription and translation 
of pro-IL-1β is modulated by molecules that are altered in neuronal injury and infection, such 
as prostaglandins, lipopolysaccharide, and glucocorticoids; glucocorticoids decrease the pro-
duction of pro-IL-1β, while lipopolysaccharides and prostaglandins, as well as intercellular 
adhesion molecules increase it [94].
The type 1 IL-1 receptor (IL-1R1) and type 2 IL-1 receptor (IL-1R2) bind to active IL-1β to 
regulate cytokine concentration. IL-1R2 acts as a decoy receptor, as it does not induce down-
stream effects upon binding to IL-1β [94]. In contrast, the type 1 IL-1 receptor induces signal 
transduction pathways in multiple cell types (endothelial cells, oligodendrocytes, neurons, 
astrocytes, microglia, leukocytes). For example, when IL-1β binds to IL-1R1 on microglia, 
cytoplasmic GTPases signal to MAPK p38α downstream to induce the transcription and 
release of other cytokines, such as TNF-α and the phagocytosis of axonal and cellular debris; 
IL-1β also induces the expression and secretion of heat shock proteins that activate other PRRs 
and expand the neuroinflammatory response [95, 96]. IL-1 receptors can also circulate in a 
soluble form to bind and impact the concentrations of IL-1 cytokines [94, 95]. The IL-1 recep-
tor antagonist, IL-1Ra, is an innate competitive antagonist to other IL-1 receptors and does not 
induce a downstream biological response [94, 95].
3.9. Inflammatory IL-1β in TBI
Numerous studies demonstrate the rapid rise of IL-1β post-injury associated with increased 
cell death. The exogenous addition of IL-1β or increased production of IL-1β post-TBI is associ-
ated with an exacerbation of injury [97–100]. For example, Lu et al. observed increased levels 
of hippocampal IL-1β as early as 3 h, peaking at 12 h and remaining for 48 h post-injury in 
a weight drop model of TBI in rats associated with severe hippocampal neuronal loss [101]. 
Lawrence et al. demonstrated an exacerbation of neuronal loss in the cortex when IL-1β was co-
administered into the ipsilateral or contralateral striatum with excitotoxin infusion in the cor-
tex. These studies provide examples of IL-1β’s global influence on cell death post-injury [102].
Accordingly, studies ablating the expression of IL-1β or inhibiting its biological effect via anti-
IL-1β antibodies, upregulation of the endogenous IL-1β receptor antagonist, IL-1Ra, or inter-
leukin-1 receptor antagonists show improvements in TBI outcomes in rat models [103–105]. 
Injury-induced neuron loss in the rat hippocampus was also significantly improved with pre-
injury intracerebroventricular administration of IL-1β antibody [101]. Post-CCI i.p. admin-
istration of anti-IL-1β antibody decreased edema at 48 h post-injury, as well as microglia 
activation, lesion size, and visuospatial learning deficits in the Morris water maze (MWM) 
task (decreased latency to the hidden platform on 2 out of 4 training days, but did not improve 
memory probe trial performance) at up to 20 days post-injury [106]. Anti-IL-1β antibody 
administration via osmotic minipump in this same CCI model resulted in decreased neutro-
phil and activated T cell penetration across the BBB into the cortex at 7 days post-injury [107]. 
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IL-1β neutralizing antibodies were also tested in a central fluid percussion injury mouse model 
of diffuse axonal TBI; IL-1β neutralizing antibodies were administered i.p. 30 min post-injury, 
improving the latency to hidden platform times in the probe trial (long-term memory) of the 
MWM task at 21 days post-injury to near sham-injured levels [108]. Decreases in the number 
of stereotypies in a multivariate concentric square field test were also seen in IL-1β neutral-
izing antibody-treated mice 2 and 9 days post-injury. Histologically, the number of microglia 
and macrophages were unchanged in treated mice [108]. The difference in IL-1β neutralizing 
antibodies’ effect on cognitive outcomes post-TBI in these models could be related to the dif-
ferent injury models used.
The genetic overexpression of the endogenous receptor antagonist to IL-1β, IL-1Ra in a closed 
head injury mouse model of TBI resulted in an improved neurologic severity score, lower 
cortical levels of harmful TNF-α, and a delayed rise in IL-1β and IL-6 at 6 versus 4 h post-
injury in wildtype mice [104]. However, in a study examining the use of the recombinant 
human IL-1Ra (i.e, anakinra), in patients with severe TBI, treatment, while safe without seri-
ous adverse effects, was found to induce a shift in cytokine levels towards an unexpected phe-
notypically M1 microglial response in comparison to non-treated controls [109, 110]. These 
findings evidence a more broadly defined role for IL-1Ra in TBI and the effect of IL-1Ra on 
microglial activation.
In a study of post-mortem TBI cortical tissue ipsilateral and contralateral to the lesion site, 
IL-1β levels were significantly higher in brains from patients with survival times ranging from 
6 to 122 h post-injury, signifying a later peak of action [71]. IL-1β CSF samples were higher 
than extracellular plasma levels of IL-1β and IL-1Ra following severe TBI in 12 patients, with 
peaks occurring 1 day and 2 days post-injury, respectively [111].
3.10. Inflammatory IL-1β in AIS
IL-1β is released from activated microglia within 30 min of ischemic stroke and appears to be 
the main IL-1 agonist induced in the brain in response to systemic or local insults [112, 113]. 
In the acute phase of injury, IL-1β interacts with its receptors to enhance microglial activation, 
stimulate astrocytic production of vascular endothelial growth factor (VEGF), and MMP-9 
from NG2-oligodendrocyte precursor cells (NG2-OPC) [114, 115]. Evidence from human 
culture systems suggests that hypoxia itself induces the production of IL-1β in endothelial 
cells, which then upregulates leukocyte adhesion molecules by an autocrine mechanism [116]. 
Additional preclinical studies have further clarified IL-1β participation in AIS pathophysiol-
ogy noting that neither IL-1β nor IL-1Ra influence glutamate release or reuptake [117, 118].
A study by Clausen et al. showed that IL-1β and TNF-α are produced by largely segregated 
populations of microglia and macrophages after AIS in mice, providing evidence of the func-
tional diversity among microglia and macrophages induced post-stroke [119]. This informa-
tion may inform the design and characterization of anti-inflammatory therapies in stroke. 
The mRNA of the natural receptor antagonist, IL-1Ra was also much higher at 12 h after per-
manent middle cerebral artery occlusion and remained elevated for up to 5 days post-stroke 
in the ischemic cortex and may reflect its effort to dampen the influence of IL-1β in the acute 
phase of AIS [120]. Multiple laboratories have examined IL-1Ra as a therapy in preclinical 
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models of AIS in mice. In a multicenter international project examining the short- and long-
term effects of IL-1Ra therapy in preclinical models of AIS, consistent decreases in lesion size 
on days 1 and 7 were noted via histology and MRI after treatment with subcutaneous IL-1Ra 
[121]. Improvements in neurologic deficits/function (“sensorimotor asymmetry”) for up to 28 
days post-treatment were also noted in this study across AIS models [121].
The potentially noxious role of IL-1β in AIS is supported by the finding that inhibition of IL-1β 
converting enzyme (ICE) decreases infarct volumes in mice [122] and rats [123]. Moreover, 
transgenic mice with a mutant ICE gene developed smaller infarcts, fewer neurological def-
icits, lower IL-1β levels and decreased DNA fragmentation after transient and permanent 
middle cerebral artery occlusion [124, 125]. Furthermore, many studies testing therapeutics in 
animal models of AIS correlate declines in IL-1β levels post-drug administration to improved 
functional and histologic outcomes post-stroke [115, 126, 127]. Thus, levels of IL-1β and IL-1Ra 
can be important predictors of the degree of neuroinflammation following ischemic stroke, 
as increased levels of IL-1β worsened AIS whereas IL-1Ra provided brain protection [114].
Clinically, a longitudinal study of patients with ischemic stroke revealed acutely increased 
mRNA levels of IL-1β, IL-8, and IL-17 in peripheral blood samples, with IL-1β and IL-8 corre-
lating with Scandinavian stroke scale scores [128]. IL-1β levels were higher in those with more 
severe neurologic impairment [128]. Increased intrathecal production of several cytokines, 
including interleukins IL-1β, IL-6, IL-8, IL-10, TNF-α, and granulocyte-macrophage colony-
stimulating factor, has also been demonstrated in patients with AIS [42, 129, 130]. In a clinical 
study involving 30 stroke patients, an early increase in intrathecal, but not systemic levels of 
IL-1β were observed post-stroke [42]. Ormstad et al. noted an association between high acute 
serum levels of glucose and IL-1β, and low IL-1Ra and IL-9 to post-stroke fatigue [21]. These 
findings support the involvement of cytokines in fatigue after stroke [21].
3.11. Inflammatory cytokine–interleukin-18
IL-18 (previously known as IFN-γ inducing factor) is a pro-inflammatory cytokine of the 
IL-1 family, namely produced by microglia in the CNS [131]. IL-18 also regulates IFN-γ sig-
naling in T-cells and Natural Killer (NK) cells [60, 76]. As previously mentioned, IL-18 can 
be activated through caspase-1 cleavage via inflammasome formation in addition to other 
proteases such as proteinase-3[94]. Activated IL-18 binds to IL-18 receptors on a variety of 
cell types to trigger downstream signal transduction pathways; the release of glutamate at 
the synapse as well as the upregulation of postsynaptic AMPA receptors in hippocampal neu-
rons is induced via IL-18 and has been shown to inhibit long-term potentiation in the dentate 
gyrus [132]. IL-18 can also induce apoptotic pathways (Fas-Fas ligand binding via induction 
of FasL expression on glia), cytotoxic immune cell activation, the extravasation of polymor-
phonuclear cells, their respiratory burst response and degranulation, as well as the release of 
matrix metalloproteinases and cytokines like TNF-α, IL-1β and IFN-γ [131].
3.12. Inflammatory IL-18 in TBI
IL-18 is heavily involved in neuroinflammation and neurodegeneration in TBI and AIS. IL-18 
levels were found to be elevated for up to 10 days post-TBI in the CSF of patients who had 
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experienced a severe head injury [133] and have been associated with more severe disability 
[134]. In a study examining serum levels of IL-18 in TBI patients, plasma IL-18 levels were ele-
vated at 7 days, 3 months, and 6 months post-injury and were noted to decrease over time in 
parallel to cognitive improvement as measured by the mini mental state examination (MMSE). 
Those with higher MMSE scores had lower levels of IL-18 at all time points [135]. In mice, 
IL-18 was elevated above control levels at 7 days post-weight drop TBI. The administration 
of the IL-18 inhibitor, IL-18-binding protein, at 1 h post-injury improved injury-induced defi-
cits involving motor function, reflexes, and normal behaviors tallied via a neurologic sever-
ity score at 7 days, but did not improve cerebral edema or behavioral deficits acutely at 24 h 
post-injury [133]. This evidences a role for IL-18 in the later phase of inflammation post-injury.
3.13. Inflammatory IL-18 in AIS
IL-18 shows a delayed rise (24–48 h) and peak (7–14 days) following ischemic stroke in mice 
[136]. However, IL-18 knockout mice showed no difference in infarct size at 24 or 48 h post-
AIS, suggesting its limited effect on lesion severity early post-AIS [137, 138].
However, examination of human atherosclerotic plaques from carotid arteries show higher 
levels of IL-18, IL-18 receptor and caspase-1 expression, with IL-18 levels highest near macro-
phages and higher in ulcerating, unstable plaques [139]. This supports a pathogenic role for 
IL-18 early in the pathophysiology of AIS, at stages of thrombus formation. In AIS patients, 
plasma IL-18 levels obtained from blood samples taken by venous access at 48 h following 
AIS in 217 patients were significantly higher than in control groups. Patients with high IL-18 
had significantly higher incidences of 90-day recurrent stroke and death. Thus, plasma IL-18 
levels could be a major independent inflammatory predictor of 90-day morbidity and mortal-
ity in AIS patients [140]. However, these observations are incongruent with a larger study 
in 2008 where IL-6, IL-18 and TNF-α levels were examined in relation to recurrent stroke 
risk. The data was obtained from the perindopril protection against recurrent stroke study 
(PROGRESS) study. It was found that IL-6 and TNF-α, but not IL-18, were associated with 
risk of recurrent ischemic stroke independent of conventional risk markers [141].
Yang et al. explored IL-18 as a potential marker for post-AIS depression. It was observed that 
serum IL-18 levels on both days 1 and 7 post-AIS were significantly higher in post-stroke 
depression patients and non-post-stroke depression patients than in non-stroke controls. 
Serum IL-18 on day 7 was significantly higher in post-stroke depression patients than in non-
post-stroke depression patients, suggesting a role for IL-18 in post-AIS changes in mood [25].
3.14. Inflammatory cytokine–interferon-γ
Interferon-γ is a classic pro-inflammatory cytokine released peripherally by activated T cells 
and natural killer cells to activate macrophages, monocytes, and microglia [33]. In any type of 
brain injury, compromise of the BBB permits the influx of peripheral T cells and NK cells, sub-
jecting CNS cells to the effects of IFN-γ. IFN-γ may exacerbate BBB permeability to periph-
eral immune cells post-injury through the upregulation of vascular cell adhesion molecule in 
astrocytes of the BBB [142]. IFN-γ then directs microglia to express neuroprotective versus 
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cytotoxic features depending on the cytokines’ concentration [143]. Microglia activated by 
low levels of IFN-γ can actually induce neurogenesis and oligodendrogenesis [143]. IFN-γ 
was also recently discovered to be released by microglia in response to IL-12 or IL-18 [144].
3.15. Inflammatory interferon-γ in TBI
In biopsies from the brains of severely injured patients, IFN-γ was detected within the first 24 h 
post-injury and was found to be higher than IL-4 and IL-6 at 3–5 days post-injury, indicating a 
robust pro-inflammatory response at up to 5 days post-TBI [145]. Post-mortem TBI brain analy-
ses show significantly increased levels of IFN-γ in brains with survival times less than 17 min 
with even higher levels in tissue ipsilateral and contralateral to the injury in brains with survival 
times ranging from 6 to 122 h post-injury [71]. In a study examining cytokine levels in patients 
with severe TBI with post-traumatic hypoxia, the duration of elevated IFN-γ levels was longer, 
persisting 5 days post-TBI, as compared to severe TBI patients without hypoxia, indicating 
more persistent neuroinflammation in TBI patients with hypoxia [146]. Experimental models 
of TBI have also investigated the time course of IFN-γ expression post-injury and have detected 
variations according to the injury type and sex. A penetrating ballistic injury model of TBI in 
male rats demonstrated rises in IFN-γ within 4 h post-injury, while a post-craniotomy weight 
drop model of TBI in female rats did not detect IFN-γ by post-injury day 2 [147–149]. CCI injury 
versus craniotomy alone in mice also showed significant increases in IFN-γ expression with 
different cytokine expression time courses, supporting the impact of injury severity on cytokine 
expression; the mild injury via craniotomy resulted in a shorter lived cytokine response, while 
the severe CCI injury resulted in a response persisting for at least 21 days. IFN-γ expression 
peaked at 3 and 7 days post-injury in CCI-injured and craniotomy mice, respectively, with CCI-
injured mice expressing higher peak levels of IFN-γ [150].
3.16. Inflammatory interferon-γ in AIS
IFN-γ has been strongly detected in autopsied human brains for up to 28 days post-ischemic 
stroke and is substantially expressed by inflammatory glia [151]. However, the rise of IFN-γ 
post-stroke may be largely facilitated by infiltrative lymphocytes, like CD4+ and CD8+ T cells, 
as IFN-γ is not present in normal brain tissue [152]. A study by Yilmaz et al. utilized the tran-
sient middle cerebral artery occlusion model of AIS in mice and knockout mice lacking various 
lymphocyte populations to assess the role, interaction, and contribution of lymphocytes and 
IFN-γ to infarct severity and functional deficits post-stroke. AIS-induced increases in plate-
let and leukocyte adhesion were significantly attenuated in CD4+ T cell knockout mice and 
CD8+ T cell knockout mice. Leukocyte adhesion also decreased in neutrophil deficient mice. 
Similarly, lymphocyte deficient mice (Rag−/− mice) and IFN-γ knockout mice had significantly 
lower levels of leukocyte and platelet adhesion post-stroke. Ischemic infarct volume was also 
lower in IFN-γ knockout mice and lymphocyte deficient (Rag1−/−) mice. In contrast, neurologic 
deficits were only improved in lymphocyte deficient Rag1−/− mice [152]. These effects were 
reversed when splenocytes were added to restore lymphocytes in Rag−/− mice [152]. While the 
absence of IFN-γ alone was enough to significantly impact infarct volume post-AIS, it was not 
sufficient to significantly change outcomes in neurologic deficits post-AIS [152].
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IFN-γ mRNA expression is also systemically increased in blood monocytes, splenocytes, and 
lymph node cells in AIS [153]. In a study by Li et al., systemic IFN-γ mRNA expression was 
increased as early as 1 h and remained elevated at 6 days, while expression levels in the isch-
emic hemisphere had a more delayed onset, rising at 12 h and remaining elevated at 6 days 
post-stroke in rats; the expression levels correlated with the infarct size [153].
IFN-γ employs the induction of adhesion molecule expression, stimulation of NADPH oxi-
dase and activation of microglial cells and other immune cells to promote neuroinflamma-
tion [154–156]. Furthermore, IFN-γ may directly induce arteriosclerosis, increasing the risk of 
ischemic stroke. A study by Tellides et al. using porcine and human artery grafts transplanted 
into immunodeficient mice showed that arteriosclerotic changes could be induced by IFN-γ 
administration alone through its interaction with vascular smooth muscle cells, without the 
presence of immune cells [157]. IFN-γ may therefore be a chief mediator of inflammatory and 
thrombogenic responses in the microvasculature.
3.17. Anti-inflammatory cytokines in traumatic brain injury and ischemic stroke
The pro-inflammatory response of effector cells in the CNS to tissue injury is opposed by 
cytokine-induced anti-inflammatory effects that initiate repair processes and curb excessive 
inflammation. Some examples are provided below.
3.18. Anti-inflammatory cytokine interleukin-10
IL-10 binds to IL-10 receptors (IL-10R) which contain two receptor subunits, IL-10R- α and 
IL-10R-β [158]. Through activation of its receptor, IL-10 induces the JAK/STAT pathway to 
decrease inflammation and the PI3K/Akt pathway, to decrease apoptosis through the upregu-
lation of anti-apoptotic factors and downregulation of caspase-3 expression [159]. Astrocytes, 
neurons and microglia generate IL-10 in the CNS, while lymphopoietic cells are responsible 
for its production outside of the CNS [160–162]. Regulatory T-cells produce IL-10 to decrease 
the activity of other T-cells and are involved in suppressing the immune response contribut-
ing to CNS injury [40]. IL-10 is involved in astroglial activation and microglia suppression to 
promote anti-inflammatory and immunosuppressive actions; microglia stimulated via TLR 
activation produce IL-10 and can have enhanced production in the presence of other signal-
ing molecules like adenosine [163]. IL-10 inhibits macrophage production of NO and ROS [70] 
and also inhibits leukocyte adhesion to the endothelium [164]. It also decreases macrophage 
and lymphocyte production of IL-1, IL-6, IL-8, TNF-α, and IFN-γ [165, 166]. Furthermore, 
IL-10 curbs inflammatory processes such as T cell generation and MHC class II antigen upreg-
ulation [167, 168].
3.19. Anti-inflammatory IL-10 in TBI
In the context of TBI, IL-10 is demonstrably higher intrathecally and has been shown to acti-
vate the anti-inflammatory subtype of microglia (phenotypically referred to as M2 microglia) 
involved in matrix formation and the remodeling of tissue [169–171]. In a study examining 
IL-10 in TBI, Knoblach et al. administered intravenous IL-10 at 30 min prior to and 1 h after 
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lateral fluid percussion TBI in rats. IL-10 administration improved motor function at 7 and 
14 days post-injury and decreased TBI-related cortical TNF-α and IL-1 expression, as well 
as hippocampal IL-1 expression at 4 h post-injury [165]. In contrast, intracerebroventricu-
larly administered IL-10 did not result in the same improvements, highlighting the systemic 
involvement of IL-10 on TBI pathophysiology [165]. Furthermore, the higher intracerebroven-
tricularly administered dose trended towards a lower survival rate than the lower dose and 
control groups [165].
In a 21-day analysis of cytokine expression post-CCI in mice, IL-10 was modestly elevated 
by day one post-injury with peak expression at 3 days post-CCI [150]. A weight drop model 
of TBI in rats showed an acute rise of IL-10 brain levels beginning 2 h post-injury followed 
by a progressive rise beginning at 4 h post-TBI; mRNA expression of IL-10 peaked within 
minutes post-injury followed by an acute drop and rebound that progressively declined over 
the remaining 24 h [98]. These findings demonstrate variability in the degree of the cytokine 
response in relation to the mechanism of injury.
Clinically, in pediatric TBI patients, IL-10 was detectable in CSF on days 1–3 post-injury [172]. 
High IL-10 levels were associated with increased mortality and with children under 4 years 
old [172]. High serum levels of IL-10 in adult patients with severe TBI were also associated 
with increased mortality and a worse GCS [173]. Csuka et al. monitored CSF and plasma 
IL-10 levels in severe TBI patients, noting that CSF levels of IL-10 were generally higher than 
serum levels, with a first peak around days 0–2 post-injury followed by a smaller peak at 7–9 
days post-injury with some individual patient variation; these levels did not correlate with 
BBB dysfunction, but correlated with different cytokines (IL-6, TNF-α) in some patients [70].
3.20. Anti-inflammatory IL-10 in AIS
In AIS, IL-10 can be released by microglia via IL-33/ST2 signaling [174]. IL-10 and IL-10R 
mRNA levels increase post-AIS with IL-10Rs noted on astrocytes in the infarct zone where 
astrocytes attempt to wall off the lesion site from viable surrounding tissue [175]. IL-10 plays 
an important role in neuroprotection post-stroke, as IL-10 knockout mice do not improve 
histologically with administration of the anti-inflammatory cytokine IL-33 post-AIS (158). 
Furthermore, IL-10 knockout mice have an exacerbated, delayed inflammatory response with 
higher mRNA levels of TNF-α, IL-1β, MMP-9, and COX-2 at day 4 post-AIS, whereas wild-
type mice express high IL-10 and IL-10R levels at this time point [175]. Studies show that 
decreased levels of IL-10 are associated with poor stroke outcomes and that administration 
of IL-10 post-stroke helps to reduce poor histological and behavioral outcomes [17, 175–179]. 
However, IL-10 knockout mice have been shown to induce a degree of immunosuppression 
post-AIS with higher levels of T-cell inhibitory CTLA-4 mRNA, phagocytic macrophages, and 
the M2 microglia marker arginase-1 at day 4 post-stroke [175].
In a clinical study, assessing the presence of IL-10 and IL-4 in AIS in relation to clinical wors-
ening, significantly lower concentrations of IL-10 were found in patients with neurological 
worsening within the first 48 h after stroke onset versus IL-4 levels which were similar in 
patients both with and without neurologic deterioration [180]. Lower plasma concentrations 
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of IL-10 were only independently associated with clinical worsening in patients with sub-
cortical or lacunar strokes [180]. Thus, IL-10 is associated with the acute neuroinflamma-
tory response in AIS, especially in those with cerebral microvascular disease or subcortical 
infarcts [180].
Another clinical study assessed the relationship between stroke severity and the serum 
levels of IL-1β, IL-2, and IL-10 in 26 patients with AIS, analyzing neurological outcome and 
interleukin levels at 72 h post-AIS. In this study, patients with lower IL-10 levels deterio-
rated neurologically within the first 72 h. Thus, IL-10 may be involved in protective mecha-
nisms during the acute phase of AIS [181]. However, IL-10’s role in AIS and post-stroke 
recovery may be influenced by additional patient characteristics, such as sex. Conway et al. 
noted that sex may interact with IL-10 levels on stroke outcomes since female patients with 
higher IL-10 levels at 24 h post-stroke were noted to have a higher incidence of post-stroke 
urinary tract infections and poorer overall outcomes [182]. However, these levels did not 
independently predict outcome, suggesting the involvement of other interacting factors 
such as age, stroke risk, stroke severity and baseline IL-10 levels pre-stroke in addition to 
sex [182].
Interestingly, pre-clinically, spontaneously hypertensive rats have been shown to have lower 
baseline IL-10 levels and a decrease in IL-10 levels within the ischemic hemisphere at 24 h 
post-AIS [183]. This contrasts with the cytokine response in normal rats who have an increase 
in IL-10 levels at 24 h post-AIS [183]. Spontaneously hypertensive rats have generally poorer 
outcomes with larger infarcts and degrees of edema [184]. These findings emphasize the influ-
ence of baseline cytokine levels and stroke risk factors, such as hypertension, in dictating 
cytokine responses, as well as stroke severity and recovery.
3.21. Anti-inflammatory cytokine interleukin-33
IL-33, a cytokine belonging to the IL-1 family, is constitutively expressed in oligodendrocytes 
and astrocytes, as well as endothelial cells [185]. IL-33 undergoes activating cleavage by cas-
pase-1 and interacts with a host of immune cells to shift the neuroinflammatory response 
towards neuroprotective, anti-inflammatory microglial and Th2 cell phenotypes, increasing 
the release of anti-inflammatory cytokines IL-4, IL-5, and IL-10, while decreasing the release 
of pro-inflammatory cytokines like TNF-α [186, 187]. IL-33 binds to suppression of tumorige-
nicity 2 (ST2) receptor, a receptor that can either be expressed on the membranes of astrocytes 
and microglia to increase microglia phagocytosis or as a soluble receptor [188].
3.22. Anti-inflammatory IL-33 in TBI
In a study examining the effects of IL-33 in a culture model of the CNS, incubation of cells 
with IL-33 resulted in microglial proliferation and triggered mRNA expression of pro-inflam-
matory markers TNF-α and IL-1β, as well as the anti-inflammatory cytokine IL-10 [188]. In 
IFN-γ stimulated microglia, IL-33 induced iNOS mRNA expression, a demonstrated neuro-
protectant in TBI [189], demonstrating the interaction of various cytokines on microglia phe-
notype [188]. More studies need to be conducted on the role of IL-33 in TBI.
Mechanisms of Neuroinflammation228
3.23. Anti-inflammatory IL-33 in AIS
In a recent study by Yang et al., mice deficient in the IL-33 transmembrane ST2 receptor had 
worse outcomes with a shift in the post-AIS response towards pro-inflammatory microglial 
behavior accompanied by larger infarcts with higher levels of neuronal cell death and poor 
behavioral performance at 7 days post-AIS, as well as higher mortality rates [174]. These find-
ings showcase ST2 signaling as an important neuroprotective factor post-AIS. Under normal 
conditions, transmembrane ST2 receptors are primarily expressed on microglia and astro-
cytes. However, following AIS, ST2 receptor expression increases in these cells, as well as 
in macrophages and neutrophils. Post-stroke IL-33 levels increase in parallel, mainly from 
oligodendrocyte and astrocyte production [174].
Administration of IL-33 in in-vivo and in-vitro models of AIS is associated with improved neu-
rologic scores, smaller infarct volumes, as well as improvements in the level of cerebral edema 
and neuronal survival with a shift towards protective microglia phenotypes [174, 186, 187]. 
IL-33’s protective effects, mediated via its ST2 transmembrane receptor, are thought to be par-
tially mediated by IL-10, as IL-33 is known to induce IL-10 production by microglia and IL-10 
knockout mice did not experience the protective, infarct shrinking effects of IL-33 administra-
tion post-AIS [174]. IL-33 administration in AIS also resulted in changes in concentrations of IL-4 
post-stroke. Korhonen et al. showed that decreases in lesion size with post-stroke IL-33 admin-
istration was associated with increases in IL-4 levels in the penumbra post-AIS and that these 
improvements diminished with the administration of anti-IL-4 antibody [186]. These observa-
tions demonstrate the interaction of IL-4 in the neuroprotective cascade induced by IL-33 [186].
Clinically, Korhonen et al. demonstrated that the soluble ST2 receptor, a decoy receptor that 
inhibits the actions of IL-33, was higher in the plasma of patients with poorer outcomes as 
measured by the modified Rankin score at 3 months post-AIS, while lower levels of this IL-33 
inhibiting receptor were associated with better outcomes [186]. In agreement with these find-
ings, serum IL-33 levels have also been found to be significantly higher in patients with AIS 
compared with healthy controls, with higher levels of IL-33 associated with smaller infarct 
volumes amongst those in the AIS group [190]. Serum IL-33 was also significantly higher in 
the patients with mild stroke as compared to the patients with severe stroke. Furthermore, 
serum IL-33 levels in AIS patients were higher in those with better functional outcomes at 3 
months [190]. In a smaller study by Liu et al. serum IL-33 levels were also increased in AIS 
patients in comparison to controls, but IL-33 levels were noted to be positively correlated with 
infarction volume [191]. These findings suggest a role for IL-33 in the pathophysiology of AIS 
and a potential use for serum IL-33 levels for diagnostic and prognostic purposes post-stroke.
3.24. Anti-inflammatory cytokine Interleukin-4
IL-4 is generated by eosinophils, mast cells, basophils, and Th2 cells and plays a role in apop-
tosis, gene expression, the Th2 immune response and cell proliferation [192]. IL-4 produced by 
T-cells has shown involvement in the formation of memories and learning; mice lacking IL-4 
as well as T-cell depleted mice have spatial memory impairments in the MWM task, reversed 
by transfer of IL-4 producing T-cells [193]. IL-4 knockout mice actually express higher levels of 
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pro-inflammatory TNF-α mRNA [192]. In a cell culture experiment, astrocytic BDNF produc-
tion, induced by IL-4, partially ameliorated the pro-inflammatory cytokine induced reduction 
in astrocytic BDNF [192]. Furthermore, IL-4 receptor complexes (type 1 and type 2) mediate 
IL-4 signaling through downstream JAK/STAT pathways to induce M2-like microglia, Th2 
cell proliferation, and growth factor release, as well as cell growth and survival via the down-
stream PI3K/Akt and PKB/mTOR pathways, evidencing its neuroprotective role [194].
3.25. Anti-inflammatory IL-4 in TBI
In pre-clinical models of TBI, IL-4 gene and protein expression peaks at 24 h post-TBI in the 
injured hippocampus of CCI–injured rats, with a largely pro-inflammatory M1 response initi-
ated more acutely within 2 h post-injury and peaking between 2 and 6 h post-injury [195]. IL-4 
and IL-13 can activate the M2a polarization state of microglia, an anti-inflammatory microglia 
subtype and may be an avenue for potential therapy post-TBI [169, 171]. Clinically, in patients 
undergoing surgery post-severe TBI, IL-4 expression levels were increased in the first 24 h 
post-injury in brain tissue samples, while lower IL-4 levels were present in patients undergo-
ing surgery on days 3–5 post-injury; in the late group, IL-4 levels were also significantly lower 
than IL-1β and IFN-γ levels [145].
3.26. Anti-inflammatory IL-4 in AIS
IL-4 is beneficial post-AIS via a variety of mechanisms. It increases the number of astrocytes 
with BDNF expression, acts on microglia to decrease their release of TNF-α, and increases 
anti-inflammatory M2 microglia; in conjunction with TGF-β2, IL-4 also activates these microg-
lia [196, 197].
A preclinical study examining the effect of IL-4 on long-term recovery and microglia/macro-
phage polarization utilized two well-established models of stroke in wild-type and IL-4 knock-
out mice [198]. In this study, IL-4 deficiency worsened neuronal loss within 5 days post-stroke 
but had no impact on neuronal tissue loss at 14 or 21 days post-stroke, suggesting a key role 
for IL-4 in earlier phases of stroke pathophysiology and recovery [198]. Lack of IL-4 promoted 
the expression of M1 microglia and macrophage markers and dampened the expression of M2 
markers at 5 and 14 days post-stroke [198]. Functionally, IL-4 knockout mice exhibited an exacer-
bation of stroke-induced sensorimotor deficits as early as 5 days post-stroke and impaired long-
term cognitive function at 21 days post-stroke [198]. Congruently, a week-long infusion of IL-4 
into the cerebral ventricles of wildtype mice post-AIS reversed the effects shown in the deficient 
IL-4 knockout mice, improving long-term sensorimotor and cognitive recovery [198]. Thus, IL-4 
may help to improve long-term neurological outcomes after stroke through anti-inflammatory 
microglia phenotypes. Additionally, a clinical study by García-Berrocoso et al. demonstrated the 
utility of the IL-4 receptor as an early biomarker of poor post-stroke outcomes [199].
3.27. Mixed inflammatory and anti-inflammatory cytokine interleukin-6
Interleukin-6 (IL-6) is involved in neuroprotective and neuroinflammatory mechanisms. IL-6 
can bind to its membrane-bound IL-6 receptor (IL-6R) or soluble IL-6 receptor (sIL-6R), both 
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of which can induce transcription through the Janus kinase/signal transducer and activator of 
transcription (i.e. JAK/STAT) pathway [200–202]. The JAK/STAT pathway is crucial to NMDA 
receptor triggered-long term depression and could possibly support synapse elimination. 
Conversely, the cytokine-activated phosphatidylinositol-3-kinase/protein kinase B (i.e. PI3K/
Akt) pathway, may support synapse survival through long term potentiation triggered by 
NMDA receptors [7, 203].
IL-6 also acts as an agonist of VEGF, which modifies tight junction proteins to disturb the 
integrity of the BBB and interferes with NO production [33, 200, 201]. Concurrently, IL-6 can 
decrease IL-1 and TNF-α synthesis in activated monocytes and may increase the production 
of IL-1Ra and soluble TNF receptors to decrease the influence of these largely pro-inflamma-
tory cytokines [204, 205]. IL-6’s neuroprotective effects have been shown to be mediated via 
the upregulation of adenosine A1 receptors on cells [206]. IL-6 also potentially aids in tissue 
remodeling and recovery through the initiation of astrogliosis and angiogenesis after injury 
[202, 207, 208].
In a hypoxic environment, such as those created by TBI or AIS, neurons undergo oxidative 
stress, excitotoxicity, and apoptosis [201]. IL-6 exerts a protective effect during these bio-
chemical processes. As part of the early response to hypoxia, neutrophils, which abundantly 
express sIL-6R, extravasate to CNS parenchyma [202]. Damaged parenchymal cells’ produc-
tion of cytokines, including IL-6, facilitate leukocyte migration to the hypoxic site. IL-6 inhib-
its TNF-α, dampening post-injury pro-inflammatory and pro-apoptotic cascades [202]. In 
the late phase of the hypoxic response, IL-6 inhibits neutrophils and recruits monocytes and 
T-cells for the initiation of the late inflammatory response [160].
3.28. IL-6 in TBI
IL-6 is upregulated in many models of TBI and demonstrates both protective and inflam-
matory effects. IL-6 knockout mice show higher levels of oxidative stress, compromised 
activation of neuroglia, an impaired inflammatory response, diminished recruitment of lym-
phocytes and restricted healing and recovery rates [66, 209–215]. Corresponding to the results 
seen in IL-6 knockout mice, GFAP-IL-6 mice, which overexpress IL-6 in the CNS, showed 
faster recovery and healing after TBI [215, 216]. Transcriptome analyses of IL-6 knockout ver-
sus wildtype [217] and GFAP-IL-6 mice [218] post-TBI via cryoinjury, showed that multiple 
pathways involving inflammation, apoptosis and oxidative stress were affected by IL-6. For 
example, IL-6 knockouts had lower expression of the gene producing suppressor of cyto-
kine signaling (SOCS), an inhibitory protein transcribed by the JAK/STAT pathway after IL-6 
activation [217]. IL-6 knockouts also expressed fewer neurotrophic genes (i.e. brain-derived 
neurotrophic factor, early growth response 1) post-injury [217]. Injured GFAP-IL-6 mice 
expressed higher levels of complement component 4 and other inflammatory mediator genes 
in addition to lower levels of select pro-apoptotic genes and oxidative stress-related genes in 
comparison to injured wildtype mice [218].
In a study of post-mortem TBI cortical tissue, IL-6 levels were significantly higher in brains 
from patients with both short survival times of less than 17 min and late survival times rang-
ing from 6 to 122 h post-injury [71]. In biopsies from contused brains in a study by Holmin 
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and Höjeberg, IL-6 expression was lower than IFN-γ and IL-1 in the late patient group (biop-
sies taken 3–5 days post-TBI) with higher expression early, at 3–24 h post-injury [145], while 
a weight drop TBI rat model study by the same authors showed delayed IL-6 expression at 
4–6 days post-injury [147]. In a study of TBI patients, plasma IL-6 levels were used to pre-
dict infectious complications and patient prognoses; higher IL-6 levels at 1-day post-injury 
predicted poorer outcomes [219]. McClain et al. observed that plasma IL-6 levels decreased 
more rapidly in patients with higher GCS scores on admission [220]. However, it must be 
stated that these correlations do not imply causality, as high IL-6 levels may not have induced 
poorer healing, but may have been simultaneously elevated in response to the severity of 
injury or pro-inflammatory response. Additional co-morbidities, such as coronary artery dis-
ease can also elevate plasma IL-6 levels, influencing detected levels post-injury [221]. The IL-6 
polymorphism (-174C/G) is also associated with fatalities in severe TBI patients [222].
3.29. IL-6 in AIS
IL-6 levels rise within 7 h post-stroke in multiple experimental animal models. This is slightly 
delayed in comparison to the rapid rise of the pro-inflammatory cytokines, IL-1β and TNF-α 
[223]. Intracerebroventricular administration of IL-6 in the rat pre- and post-stroke resulted in 
significantly smaller lesions [224], while IL-6 knockout mice had significantly larger lesions 
and higher mortality when body temperature was regulated [225], supporting the protective 
role of IL-6 in stroke.
IL-6 has also demonstrated a role in angiogenesis post-stroke. An experiment utilizing IL-6 
knockout mice showed exacerbation of lesion volumes and a reduction in angiogenesis and 
regional cerebral perfusion at 4 weeks post-stroke [208]. In-vitro models of ischemia after IL-6 
administration, resulted in increased IL-6 mRNA expression in neurons, glial cells, and endo-
thelial cells, as well transcription of genes associated with neovascularization [208]. However, 
a clinical study by Smith et al. correlated peak IL-6 levels in the first week post-AIS with 
worse outcomes as measured by the modified Rankin score at 3 months and larger ischemic 
volumes [45]. A study by Acalovschi et al. showed that the post-AIS inflammatory response 
due to IL-6 expression is influenced by genetic variation and that the induction of the inflam-
matory response by IL-6 might be enhanced by a transient downregulation of the potential 
IL-6 antagonist sgp130 [44].
4. Cytokine modulation as therapeutic interventions
Various agents have been used to decrease the pro-inflammatory response and augment the 
anti-inflammatory response post-TBI and post-AIS. Antibiotics, steroids, anesthetics, immuno-
modulating therapies, non-steroidal anti-inflammatory agents, as well as hormonal therapies 
and nutritional supplements have been shown to impact the immune response post-brain injury 
in pre-clinical and some clinical studies. However, findings in animal models pre-clinically do 
not always translate clinically. For example, cytokines have been detected in the CSF of TBI 
patients for up to 1 year post-injury while detected more transiently in animal models of TBI [92]. 
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Furthermore, cytokine modulation does not always correlate with positive functional outcomes, 
as treatments may need to be tailored to injury severity and mechanism, patient genotype and sex, 
immune response time course, and particular cytokine targets, details of which may be obtained 
through cytokine biomarker identification and monitoring. Currently, there are no acceptable 
therapeutics for TBI, as management is limited to skull fracture repair, control of increased intra-
cranial pressure and stabilization of the primary injury [10]. The only FDA-approved agent for 
AIS is intravenous tissue plasminogen activator (tPA) which dissolves clots up to 4.5 h post-stroke 
symptom onset. FDA-approved retrievable stent devices are also now recommended to physi-
cally remove clots in large vessels within an acute time window of up to 6 h post-stroke symptom 
onset in eligible patients [17, 226].
4.1. The antibiotic minocycline in AIS and TBI
The tetracycline antibiotic minocycline alters inflammatory cytokine production post-TBI and 
post-AIS, thus improving functional and histological outcomes. Bye et al. examined minocy-
cline in a closed head injury model of TBI in mice and observed that administration of mino-
cycline acutely decreased lesion volume and functional deficits at 1 day post-injury [227]. In a 
study by Yang et al. examining minocycline administration post-AIS in spontaneously hyper-
tensive rats, infarct size and degree of tissue loss/damage in the ischemic hemispheres were 
reduced as seen via magnetic resonance imaging and apparent diffusion coefficient mapping 
at two and 4 weeks post-AIS [228]. Minocycline treatment also reduced AIS-induced levels 
of TNF-α and IL-1β, and increased levels of TGF-β, IL-10, anti-inflammatory M2 microglia/
macrophage markers, as well as cerebral perfusion [228]. Small clinical studies of minocycline 
in AIS have shown a decrease in IL-6 levels at 24 h post-AIS [229] and have proven safety in 
AIS patients both with and without tPA administration [230]. Lampl et al. showed improve-
ments in functional recovery as measured by the NIH stroke scale (NIHSS), modified Rankin 
scale (mRS) and Barthel index(BI), in patients started on 200 mg of minocycline for 5 days 
within 6–24 h of stroke onset [231]. Srivastava et al., utilizing the same treatment paradigm as 
Lampl et al., found improved mRS and BI scores at 3 months post-AIS in those treated with 
minocycline [232]. The same treatment paradigm was also utilized by Amiri-Nikpour et al. 
who reported improved NIHSS scores at 30, 60 and 90 days post-AIS in male patients receiv-
ing minocycline [233]. Kohler et al. utilized lower doses of minocycline (five 100 mg doses) 
and saw no improvement in NIHSS at 7 days nor in the mRS or BI at 90 days post-AIS [234].
Minocycline administration in multiple adult animal models of TBI has been shown to decrease 
activation of microglia, improve functional behavioral deficits such as spatial memory deficits 
and post-TBI anxiety [235], and decrease caspase activation and markers of neuroinflamma-
tion and damage [236]. In a study examining the use of minocycline in a blast injury model of 
TBI in rats, researchers noted a decrease in post-TBI anxiety via the elevated plus maze at 46 
days post-injury accompanied by decreased corticosterone levels and improvements in spa-
tial memory via Barnes maze testing post-injury as late as 47 days post-TBI [237]. Minocycline 
administration also decreased inflammatory and neuron and glial injury-associated markers 
c-reactive protein, monocyte-chemotactic protein-1, neuron-specific enolase, S100 β, tau, and 
neurofilament H in this study [237].
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In contrast to findings in adult TBI models examining minocycline, in a neonatal model of TBI, 
minocycline did not improve functional deficits and actually worsened microglial activation 
and neurodegeneration, highlighting the influence of age on TBI pathophysiology and thera-
peutic selection [238]. In contrast, in a study of minocycline in neonatal ischemia, microglial 
activation was not affected, but lesion volume was reduced [239]. Minocycline was also shown 
to reduce apoptosis and excitotoxicity in neonatal hypoxic-ischemic injury in rats, suggesting 
a more extensive use for minocycline in ischemic pathologies [240].
To establish the use of minocycline in focal embolic stroke with comorbidities, Type 1 dia-
betic rats underwent embolic stroke and were given minocycline with or without tPA. It 
was observed that compared with treatments of saline or tPA alone, minocycline plus tPA 
combination therapy significantly reduced brain infarction, intracerebral hemorrhage, and 
hemispheric swelling at 24 h after stroke. The combination also significantly suppressed 
stroke-induced elevations in plasma levels of MMP-9 and IL-1β up to 24 h after stroke (57).
4.2. Biological response modifiers in TBI and AIS
IL-1R antagonists are currently being examined in AIS and TBI both pre-clinically as discussed 
above and clinically. A meta-analysis analyzing IL-1R antagonists in rodent models of stroke, 
reported an overall decrease in infarct volumes and an improvement in functional outcomes 
[241]. A recent cross-laboratory study of subcutaneous IL-1R antagonist treatment in AIS also 
found consistent decreases in neurologic deficits and lesion volume across preclinical models 
of AIS in multiple laboratories [121]. Pradillo et al. demonstrated that post-AIS subcutaneous 
administration of IL-1Ra in old rats with comorbidities and in young rats increased neuro-
genesis and functional outcomes in both populations [242]. IL-1R antagonists have also been 
proven pre-clinically to reach therapeutic levels via intranasal administration, decreasing IL-1β 
and TNF-α levels post-stroke in a rat model [243]. IL-1R antagonists compete with IL-1β and 
IL-1α for IL-1R binding, preventing downstream pro-inflammatory cascades from being acti-
vated, thus exerting a neuroprotective effect. Emsley et al. showed the safety of a recombinant 
human IL-1R antagonist administered post-AIS which also incidentally showed lower levels 
of IL-6 and peripheral inflammation, in addition to improved clinical outcomes [244]. A phase 
II clinical trial examining the use of subcutaneous IL-1R antagonist, anakinra, initially admin-
istered within 6 h post-stroke with repeat dosing every 12 h for a total of 6 injections over 72 
h (ISRCTN74236229) has recently been completed. In TBI, as previously stated, Helmy et al. 
showed the safety of IL-1R antagonists, but actually reported an increase in the pro-inflamma-
tory M1 microglia phenotype, acknowledging the variation in the immune response depending 
on the mechanism of injury [109]. The off-label perispinal administration of the anti-TNF-α 
monoclonal antibody, etanercept in post-stroke cognitive dysfunction and TBI have demon-
strated benefit as well [245]. Studies by Chio et al. have demonstrated that post-TBI i.p. admin-
istration of etanercept in the fluid percussion model of brain injury in the rat improves motor 
deficits at 7 days and increases markers of neurogenesis [246], decreases acute TBI-induced 
rises in glutamate, the lactate/pyruvate ratio, and improves injury-induced motor deficits [247], 
cognitive deficits in the passive avoidance task [248], and the severity of ischemia at 3 days 
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post-injury [247, 248]. A major barrier to the efficacy of etanercept as a TNF-α inhibitor for 
AIS and TBI is its poor BBB permeability due to its large size. Therefore, formulations of TNF 
decoy receptors with better BBB penetrance have been designed and tested in both TBI and AIS. 
Sumbria et al. show the utility of cTfRMAb-TNFR fusion protein (carboxy terminal transferrin 
receptor monoclonal antibody-TNF receptor), a genetically engineered monoclonal antibody 
against the mouse transferrin receptor found in the BBB linked to the TNF receptor to achieve 
whole molecule transfer into the brain, post-AIS. The administration of intravenous cTfRMAb-
TNFR at 45 min post-AIS in mice resulted in significant decreases in subcortical, cortical, and 
hemispheric stroke volume, in addition to a 54% reduction in neurologic deficits at 24 h and 7 
days post-AIS [249]. Clausen et al. examined the use of a dominant-negative inhibitor of soluble 
TNF called XPro1595 versus etanercept which inhibits both soluble and transmembrane TNF, 
in a mouse model of AIS. While infarct size was not affected, XPro1595 administration resulted 
in a decrease in granulocyte influx into the infarct, and improvements in motor and somatosen-
sory function as measured by symmetrical grip strength, rotarod performance, and horizontal 
rod slip testing [250]. Simultaneously, the acute phase response in the liver was decreased by 
etanercept administration, indicating the importance of transmembrane TNF-α on the periph-
eral immune response [250]. TNF-α inhibitors, 3,6′ dithiothalidomide, TNF-α binding protein, 
and pentoxifylline have also been explored to achieve adequate TNF-α inhibition post-brain 
injury [69, 72, 251] and post-AIS [252–255], demonstrating improved histologic and behavioral 
outcomes. More recently, a third generation thalidomide, pomalidomide, was also shown to 
decrease neuronal cell death and curb neuroinflammation via a large decrease in TNF-α con-
centration, in addition to improving motor and sensory functional deficits when administered 
as late as 5 h post-TBI in rats [256]. Additional biologic TNF-α inhibitors, such as infliximab 
and adalimumab, currently approved for the treatment of inflammatory and autoimmune dis-
eases, such as rheumatoid arthritis, may prove beneficial in AIS and TBI. B-cells have been 
detected in the brain post-injury due to increased BBB permeability, permitting their infiltra-
tion into the brain parenchyma, and have been shown to mediate inflammation in an animal 
model of stroke resulting in delayed post-stroke cognitive impairment [257]. An analog of the 
biologic B-cell inhibitor drug, Rituximab, has been shown to decrease B-cell infiltration across 
the BBB and improve post-stroke cognitive impairment when administered to mice at 5 days 
post-stroke with biweekly doses for 7 weeks [257].
4.3. Hormonal modulation
Hormonal intervention also impacts post-injury cytokine expression and has been exam-
ined in AIS and TBI. Pre-clinically, progesterone administration post-TBI and post-AIS has 
been shown to decrease edema, lesion size, excitotoxicity, apoptosis, free radical production, 
microglial activation and pro-inflammatory cytokines like TNF-α and IL-1β, while promot-
ing remyelination and short-term functional preservation [258, 259]. However, these benefits 
have not been able to translate clinically. While the pilot phase II ProTECT trial (progester-
one for traumatic brain injury, experimental clinical treatment) and a randomized controlled 
trial of progesterone in severe TBI in China showed improved outcomes and decreased mor-
tality in TBI patients, the larger phase III SyNAPSe trial (study of a neuroprotective agent, 
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progesterone in severe traumatic brain injury) and phase III PROTECT trial showed no ben-
efit [260–263]. Progesterone has not been tested clinically in AIS patients.
4.4. Omega-3 fatty acids
Administration of omega-3 fatty acids in pre-clinical animal studies of TBI and AIS have been 
demonstrated to decrease post-injury neuronal death, curb increases in pro-inflammatory 
cytokine IL-1β and caspase-1 and functional deficits post-TBI [264]. In TBI, pre-injury admin-
istration of omega-3 fatty acids in rats’ diet and via gavage resulted in decreases in neuronal 
cell death, edema, lesion volume, caspase-1, IL-18, IL-6 and IL-1β, as well as functional defi-
cits in MWM and beam balance; these effects were largely mediated via G-protein coupled 
receptor 40 (GPR40), as blockage of this receptor reversed these benefits [264]. In patients, fish 
consumption has been correlated to decreased cerebrovascular disease risk, but omega-3 fatty 
acid supplementation alone has not been associated with decreased risk [265]. However, in a 
study of spontaneously hypertensive rats at increased risk for stroke, glucose utilization and 
cerebral perfusion were improved with omega-3 fatty acid administration [266]. A clinical 
trial in Japan examining statin therapy in combination with the omega-3 fatty acid, eicosa-
pentaenoic acid, versus statin therapy alone, demonstrated a decreased incidence of recurrent 
stroke of 20% within 5 years [267].
4.5. N-acetylcysteine
N-acetylcysteine has been shown to have anti-inflammatory and antioxidant actions, increas-
ing glutathione synthesis to scavenge ROS, decreasing IL-1β and TNF-α levels in brain injury, 
decreasing caspase-3 levels, and shifting microglia towards M2 anti-inflammatory pheno-
types [268–271].
A pre-clinical experiment evaluating the modulation of oxidative stress with N-acetylcysteine 
and selenium treatments in TBI demonstrated that use of these treatments affected the oxi-
dant and antioxidant, pro- and anti-inflammatory cytokines balance in rats by both down-
regulating IL-1β, a pro-inflammatory cytokine, and up-regulating IL-4, an anti-inflammatory 
cytokine [272]. N-acetylcysteine administered 30 min post-TBI in rats resulted in improved 
MWM performance to near sham-injured levels [273]. When administered 60 min post-weight 
drop injury in mice, functional deficits in novel object recognition and Y-maze were signifi-
cantly improved [273]. In combination with minocycline, N-acetylcysteine has been shown to 
act synergistically to reduce TBI-induced demyelination, augment M2 microglia activation in 
white matter and modulate TBI-induced neuroinflammation, increasing microglial activation 
yet decreasing the number of injury-induced phagocytic CD68+ macrophages in the corpus 
callosum. The combination also improves learning and long-term retention in the active place 
avoidance task [274]. Clinically, N-acetylcysteine has been tested in a double-blind, placebo 
controlled study of blast-induced mild TBI; mild TBI symptoms included balance dysfunc-
tion, headache, hearing loss, neurocognitive dysfunction and confusion. Patients receiving 
N-acetylcysteine within 24 h of blast injury had fewer to none of these symptoms on day 7 
post-treatment with 86% of treated patients experiencing complete symptom resolution by 
day 7 versus 42% in those receiving placebo [275].
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N-acetylcysteine has also shown efficacy in AIS. In a rat model of AIS, N-acetylcysteine 
administration reduced infarct volume, apoptosis, as well as TNF-α, IL-1β, and iNOS expres-
sion [276]. Functionally, rats receiving N-acetylcysteine had improved motor function [275]. 
Additional studies showed reduced levels of AIS-induced hippocampal cell death with 
N-acetylcysteine administration [277] and decreased ischemia evoked levels of Nuclear factor 
kappaB [271].
4.6. Cannabinoids
In a closed head injury model of TBI in rats, Dexanabinol (HU-211), a synthetic cannabinoid 
that inhibits TNF-α as well as NMDA receptors and free radical proliferation has been shown 
to reduce BBB breakdown, edema, and functional deficits [278]. Dexanabinol has also been 
shown to improve deficits in animal models of AIS [279]. In TBI patients, a phase II clinical 
trial examining the administration of i.v Dexanabinol within 6 h post-injury was observed 
to improve rises in intracranial pressure 2–3 days post-injury with non-significant increases 
in Glasgow outcome scores at 6 months in patients with more severe injuries at presentation 
[280]. However, in the larger phase III trial of Dexanabinol for severe TBI, no benefits were 
seen, indicating the need for larger sample sizes and well-defined exclusion criteria and out-
come measures to detect true effects [281]. Despite the failure of Dexanabinol, other cytokine-
modulating cannabinoids continue to be evaluated and show potential utility in TBI and AIS. 
The endocannabinoid, 2-arachidonoylglycerol, has been shown to decrease pro-inflammatory 
cytokine expression, decrease breakdown of the BBB and post-injury edema pre-clinically in a 
closed head injury model of TBI [282, 283].
5. Brain inflammation and brain injury–conclusions
This chapter has focused on the role of select cytokines in the pathophysiology of TBI and AIS. 
By reviewing pre-clinical and clinical studies from the TBI and AIS literature, one can identify 
hypotheses that have been successfully confirmed in patient populations and identify gaps 
in the translation of pre-clinical observations to the hospital wards. In translating concepts 
from preclinical studies one must be cognizant of the variability in the patient populations 
examined. For example, the impact of the TNF-α polymorphisms identified in Caucasians and 
Asians would likely impact the efficacy of TNF-α targeting treatments in these populations. 
Common cytokine gene polymorphisms should continue to be studied in detail to understand 
variations in the AIS and TBI-induced inflammatory responses in different patient groups 
[284]. Various mechanisms of TBI ranging from blunt injury to blast versus penetrating injury 
also induce distinct cytokine responses as described above. Therefore pre-clinical trials of ther-
apeutics as well as the spatiotemporal characterization of cytokine expression should examine 
multiple modalities of injury and ischemic insults (embolic versus thrombotic). Effects noted 
consistently across multiple models of TBI and AIS are more likely to translate clinically.
The pathophysiology of AIS and TBI have significant overlap with similar cytokine roles post-
injury. Using genetic knockout studies, the particular role of cytokines in these conditions has 
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been well defined. However, modulation of cytokine expression just prior to injury, rather 
than from conception is more informative to the molecule’s role in AIS and TBI. Knockout or 
inhibition of TNF-α, IL-1β, IFN-γ, and IL-18 improved outcomes (see Figure 3). In contrast, 
addition or overexpression of IL-10, IL-33, IL-6, and IL-4 improves AIS and TBI outcomes (see 
Figure 3).
Treatments blocking pro-inflammatory and upregulating anti-inflammatory cytokines thr-
ough receptor inhibition, synthesis inhibition versus induction, neutralizing antibodies, and 
Figure 3. Summary of cytokines reviewed. Knockout or inhibition of TNF-α, IL-1β, IFN-γ, and IL-18 improved 
outcomes in AIS and TBI. TNF-α can induce cell survival and proliferation, but has been demonstrated to also 
induce apoptosis via TNFR2 and TNFR1. IFN-γ can induce neuro- and oligodendro-genesis at low concentrations, 
while higher concentrations cause leukocyte adhesion, arteriosclerosis, and increase the ratio of Th1:Th2 cells via 
upregulation of IP-10. IFN-γ, IL-18, and IL-1β promote TNF-α expression. IL-18 causes apoptosis, MMP and PMN 
release and activation, while IL-1β promotes heat shock protein release and leukocyte adhesion. In contrast, addition 
or overexpression of IL-10, IL-33, IL-6, and IL-4 improves outcomes. IL-6 decreases TNF-α and IL-1β, while promoting 
angiogenesis and astrogliosis. IL-33 leads to iNOS release and anti-inflammatory Th2 cells and microglia, in addition 
to the promotion of IL-10 and IL-4. IL-10 decreases brain injury and the cytokines IL-1, IL-8, IL-6, TNF-α, and IFN-γ, 
while inhibiting nitric oxide, reactive oxygen species, and leukocyte adhesion, as well as apoptosis and caspase-3. IL-4 
increases BDNF, anti-inflammatory microglia, and decreases TNF-α expression. Abbreviations: BDNF, brain-derived 
neurotrophic factor, IP-10, interferon gamma-induced protein 10 (i.e. C-X-C motif chemokine 10), iNOS, inducible 
nitric oxide synthase, MMP, metalloproteinase, NO, nitric oxide, PMN, polymorphonuclear cells, Th1 cell, T-helper 
cell type 1, Th2 cell, T-helper cell type 2, TNFR2, TNF-α receptor 2, TNFR1, TNF-α receptor 1, ROS, reactive oxygen 
species.
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inflammatory response modulators have shown promise. The ratio of pro-versus anti-inflam-
matory cytokines, as well as baseline cytokine levels may allow one to gauge the overall pro-
gression of injury in AIS and TBI to better intervene or establish prognoses. Computational 
modeling of cytokine patterns and interactions in AIS and TBI of different severities with or 
without co-morbidities or genetic predispositions may help to further predict how changing 
one or more variables can impact overall pathophysiology and prognosis.
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